Drug Profile
BMS 816336
Latest Information Update: 11 Nov 2013
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 07 Nov 2013 Discontinued - Phase-I/II for Diabetes mellitus in USA (PO)
- 31 Mar 2010 Bristol-Myers Squibb completes a phase I trial in healthy volunteers in Australia